STI Prophylaxis and Emergence of Antimicrobial Resistance

Launched by UNIVERSITY COLLEGE, LONDON · Jan 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of using antibiotics, specifically doxycycline, to prevent sexually transmitted infections (STIs) and how this might lead to antibiotic resistance. The researchers want to learn more about how this use of antibiotics affects the bacteria that naturally live in our bodies, particularly in the throats and guts of men who have sex with men (MSM). They will recruit 108 participants, some of whom are using doxycycline for STI prevention and some who are not, to see if there are any differences in bacterial behavior between the two groups.

To be eligible for this study, participants need to be at least 18 years old, identify as male (either cisgender or transgender), and have sexual relations with men. Participants will need to visit the clinic every six months, where they will provide samples from their throat and stool, as well as answer some questions. The aim is to make it easy to find out if antibiotic resistance is happening and how it might affect the good bacteria in their bodies. This study is currently recruiting, and it's an important step in understanding how antibiotic use for prevention may impact health.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Aged ≥ 18 years.
• • Identifies as a man (cis or trans).
• • Has sex with men.
• • Able to provide informed consent.
• Exclusion Criteria:
• • Use of an antibiotic other than doxycycline in the 3 months prior to enrolment
• • Currently being treated for an STI with doxycycline
• • Use of doxycycline within the prior 3 months for an indication other than STI treatment or STI prevention.